What is happening behind the scenes at the pharmaceutical company?
When the company's chairman opens his wallet and buys stocks from his own pocket in the open market, it makes us try to understand.
Let's dive in.
Who is Lexicon anyway?
This is a biopharmaceutical company that operates using a 'reverse genetics' approach.
Instead of starting with a disease and trying to 'shoot in all directions' until a drug is found, Lexicon tries to start by identifying a specific protein in the body related to the disease, and then develops a drug precisely targeting it.
This is focused medicine aiming for high efficacy with fewer side effects.
Growth drivers
1. INPEFA (sotagliflozin)
A drug that has already received FDA approval. It is intended to reduce the risk of mortality and hospitalizations from heart failure.
The company's challenge: market penetration and adoption rate.
Last month (January), the company announced a collaboration with Viatris for the international launch of the drug.
2. LX9211 - an innovative drug in the pain field
As of January 2026, it completed Phase 2 and is in Phase 3 clinical trials for the treatment of neuropathic pain in diabetic patients.
Phase 3: testing real efficacy in humans.
3. Zynquista
The company is awaiting the regulator's decision for NDA approval for the treatment of type 1 diabetes patients with kidney disease.
Through the NDA application, the company essentially seeks to officially receive regulatory approval for marketing.
This stage places the company before a binary event: approval or rejection.
4. LX9851 (in partnership with Novo Nordisk) - a drug for obesity treatment
In January 2026, Lexicon received a $10 million payment from Novo Nordisk upon reaching a development milestone. Lexicon is eligible for up to an additional $950 million, provided it achieves future milestones.
And what is happening behind the scenes at the company this month? (February)
We identified cumulative insider purchases of approximately $2.5 million in less than three weeks.
Who is the buyer?
Raymond Debbane
Chairman of the board since 2005 and founder of Invus.
He purchased approximately 2 million shares through his investment fund, Invus Global Management.
We delved into institutional investor data, where a relative increase in holdings by several institutional bodies was recorded, alongside dynamic trading movements:
- UBS Bank increased its holdings in the company by 752% in the last quarter.
- Jane Street Group increased its holdings in the company by 277%.
The company's continued activity is now expected to be primarily influenced by:
Sales rate, clinical results
And based on these parameters, the next chapters in Lexicon's chronicle will be written.
We are monitoring.